Quantinno Capital Management LP Grows Stock Holdings in Royalty Pharma plc (NASDAQ:RPRX)

Quantinno Capital Management LP increased its holdings in Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 30.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 73,380 shares of the biopharmaceutical company's stock after buying an additional 16,945 shares during the quarter. Quantinno Capital Management LP's holdings in Royalty Pharma were worth $1,872,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its position in shares of Royalty Pharma by 4.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,131,628 shares of the biopharmaceutical company's stock valued at $79,888,000 after buying an additional 130,025 shares in the last quarter. Jupiter Asset Management Ltd. bought a new stake in Royalty Pharma during the 4th quarter worth approximately $4,950,000. Allspring Global Investments Holdings LLC lifted its holdings in Royalty Pharma by 303.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 539,995 shares of the biopharmaceutical company's stock valued at $13,926,000 after purchasing an additional 406,123 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in Royalty Pharma by 9.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 94,208 shares of the biopharmaceutical company's stock valued at $2,403,000 after purchasing an additional 8,018 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of Royalty Pharma in the fourth quarter worth approximately $486,000. 54.35% of the stock is currently owned by institutional investors.

Royalty Pharma Price Performance

Shares of Royalty Pharma stock traded up $0.19 on Tuesday, hitting $32.64. 517,566 shares of the company traded hands, compared to its average volume of 3,465,726. Royalty Pharma plc has a 52 week low of $24.05 and a 52 week high of $34.32. The business has a 50-day simple moving average of $32.38 and a 200 day simple moving average of $30.26. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.44 and a current ratio of 1.44. The stock has a market capitalization of $18.81 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 2.31 and a beta of 0.49.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. The company had revenue of $839.00 million for the quarter, compared to the consensus estimate of $724.69 million. Research analysts expect that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $0.22 dividend. The ex-dividend date is Friday, May 16th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 2.70%. Royalty Pharma's dividend payout ratio is currently 47.57%.

Analyst Ratings Changes

Several analysts have recently commented on RPRX shares. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a research note on Friday, March 28th. Finally, Morgan Stanley began coverage on Royalty Pharma in a research report on Friday, May 16th. They issued an "overweight" rating and a $51.00 price objective on the stock. Two investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Royalty Pharma currently has an average rating of "Moderate Buy" and a consensus target price of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.